Mureidomycin B
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Category | Antibiotics |
Catalog number | BBF-02565 |
CAS | 114797-05-6 |
Molecular Weight | 842.91 |
Molecular Formula | C38H50N8O12S |
Purity | 95% |
Online Inquiry
Description
Mureidomycin B is an antibiotic produced by Str. flavidovirens SANK 60486. It has anti-Pseudomonas aeruginosa activity.
Specification
Synonyms | 2-[[1-[[3-[[2-amino-3-(3-hydroxyphenyl)propanoyl]-methylamino]-1-[[5-(2,4-dioxo-1,3-diazinan-1-yl)-4-hydroxyoxolan-2-ylidene]methylamino]-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]carbamoylamino]-3-(3-hydroxyphenyl)propanoicacid; 114797-05-6; 2-[[1-[[2-[[2-amino-3-(3-hydroxyphenyl)propanoyl]-methyl-amino]-1-[[(E)-[5-(2,4-dioxo-1,3-diazinan-1-yl)-4-hydroxy-oxolan-2-ylidene]methyl]carbamoyl]propyl]carbamoyl]-3-methylsulfanyl-propyl]carbamoylamino]-3-(3-hydroxyphenyl)propanoicacid; ACMC-20mkt6; CTK0I2527 |
IUPAC Name | 2-[[1-[[3-[[2-amino-3-(3-hydroxyphenyl)propanoyl]-methylamino]-1-[[(E)-[5-(2,4-dioxo-1,3-diazinan-1-yl)-4-hydroxyoxolan-2-ylidene]methyl]amino]-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]carbamoylamino]-3-(3-hydroxyphenyl)propanoic acid |
Canonical SMILES | CC(C(C(=O)NC=C1CC(C(O1)N2CCC(=O)NC2=O)O)NC(=O)C(CCSC)NC(=O)NC(CC3=CC(=CC=C3)O)C(=O)O)N(C)C(=O)C(CC4=CC(=CC=C4)O)N |
InChI | InChI=1S/C38H50N8O12S/c1-20(45(2)34(53)26(39)16-21-6-4-8-23(47)14-21)31(33(52)40-19-25-18-29(49)35(58-25)46-12-10-30(50)43-38(46)57)44-32(51)27(11-13-59-3)41-37(56)42-28(36(54)55)17-22-7-5-9-24(48)15-22/h4-9,14-15,19-20,26-29,31,35,47-49H,10-13,16-18,39H2,1-3H3,(H,40,52)(H,44,51)(H,54,55)(H2,41,42,56)(H,43,50,57)/b25-19+ |
InChI Key | DXBJHRPKFQGVGZ-NCELDCMTSA-N |
Properties
Appearance | White Powder |
Antibiotic Activity Spectrum | Gram-negative bacteria |
Density | 1.449 g/cm3 |
Reference Reading
1.Intrinsic resistance of Escherichia coli to mureidomycin A and C due to expression of the multidrug efflux system AcrAB-TolC: comparison with the efflux systems of mureidomycin-susceptible Pseudomonas aeruginosa.
Gotoh N1, Murata T, Ozaki T, Kimura T, Kondo A, Nishino T. J Infect Chemother. 2003 Mar;9(1):101-3.
Intrinsic resistance to mureidomycin is shown in Escherichia coli. This is in contrast to Pseudomonas aeruginosa, which generally displays intrinsic resistance to a variety of antimicrobial agents, but not to mureidomycin. Isogenic efflux system mutants from both species were subjected to antibiotic susceptibility tests. These studies showed that the differences regarding the susceptibility of E. coli and P. aeruginosa to mureidomycin A and C may be explained by the expression of efflux systems that mediate resistance to mureidomycin A and C.
Recommended Products
BBF-03904 | Nosiheptide | Inquiry |
BBF-01210 | Emericid | Inquiry |
BBF-03868 | Honokiol | Inquiry |
BBF-01829 | Deoxynojirimycin | Inquiry |
BBF-02627 | Rapamycin | Inquiry |
BBF-03427 | Tubercidin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳